EVMN 8-K 2026-11-04

Evommune, Inc. (EVMN) 8-K dated 2026-11-04 — accession 0001193125-26-447608.

Evommune, Inc. (EVMN) common stock.

Evommune, Inc. filed a 8-K on 2026-11-04. Accession 0001193125-26-447608.

This 8-K covers: Material agreement (Item 1.01), Unregistered share sale (Item 3.02), Reg FD disclosure (Item 7.01), Other events (Item 8.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported EVMN revenue for 2025-12-31 was $13.0M. Net income was -$68.9M. Revenue was up 85.7% from 2024-12-31 to 2025-12-31. EVMN currently screens at market cap $215.6M.

Not investment advice. The EVMN SEC hub lists recent forms. The stock page is the research view.